Glenmark Pharma strengthens on plan to sell oral contraceptive product division

Glenmark Pharmaceuticals is in talks with some leading local and global drug makers, for the sale of its oral contraceptive product division, which manufactures generic anti-pregnancy medicine. The company has almost the entire range of about 19 variants of the oral contraceptive, which includes its existing product line and ANDAs pending approvals. The niche hormonal product is manufactured at the company's factory in Goa and has a market size of more than $2.5 billion in the US.

With few players managing to enter this segment due to its complex manufacturing technology, the product is a high-margin product. Further, Glenmark is the third company after Israel's Teva and American Actavis Inc with the capability of manufacturing this product.

Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Godrej Consumer Products soars on plan to set up factories in Tanzania and Uganda

The promoters holding in the company stood at 63.32% while institutions and non-institutions held 29.48% and 7.20% respectively.

With an view of expanding its manufacturing footprints in Africa, Godrej Consumer Products is gearing up to set up factories in Tanzania and Uganda. Further, the company, which so far has made four acquisitions in Africa is in talks to take over some local firms in the continent.

Presently, the company has manufacturing facilities in four countries in Africa-South Africa, Mozambique, Kenya and Nigeria. Nevertheless, the company is betting big on the African market to drive its international sales, given that sales from African operations already account for 25% of total international sales.

Godrej Consumer Products is a leader among India's Fast Moving Consumer Goods companies, with leading Household and Personal Care Products. Its brands include Good Knight, Cinthol, Godrej No. 1, Expert, Hit, Jet, Fairglow, Ezee, Protekt and Snuggy, among others, which are household names across the country.

Jindal Poly Films soars on completing acquisition of ExxonMobil’s BOPP Global business

Jindal Poly Films has (JPFL) has completed the acquisition of ExxonMobil’s Global business of BOPP, which accordingly has led to change in control. The company, in this respect, had signed the Framework Agreement in the month of October, 2012 and the Sale Purchase Agreement in the month of May, 2013. With this acquisition, the company is one of the leading manufacturers of flexible packaging films globally with a combined capacity of approximately 1.45,000 tonnes per annum for BOPP films.

Further, the transaction covers five BOPP production locations in the U.S and Europe, with the manufacturing sites being in Georgia and Oklahoma in the U.S. and in Italy, the Netherlands, and Belgium in Europe. The transaction also includes a technology center and sales office in Rochester, New York, and an office in Luxembourg.

Jindal Poly Films is a part of the diversified B C Jindal group. The group has interests in flexible packaging, photographic products, thermal power generation and steel products. It has the world’s single largest site for production of BOPP and BOPET films at Nasik, India. Its current combined capacity of BOPET and BOPP is 337,000 tonnes/annum and its annual sales turnover as on March 2012 was $452 million.

Lupin surges as its arm launches generic Zymaxid Ophthalmic solution in the US

Lupin’s - US subsidiary, Lupin Pharmaceuticals, has launched its generic Gatifloxacin Ophthalmic Solution in the US, 0.5%. Lupin had earlier received final approval from the United States Food and Drugs Administration (US FDA) to market a generic version Allergan Inc's Zymaxid Ophthalmic Solution, 0.5%.

Lupin's Gatifloxacin Ophthalmic solution 0.5% is the generic equivalent of Zymaxid Ophthalmic Solution of Allergan and is indicated for the treatment of bacterial conjunctivitis. Zymaxid Ophthalmic Solution, 0.5%, had annual U.S. sales of approximately $ 62.3 million (IMS MAT Jun 2013). Lupin was the first applicant to file an ANDA for Zymaxid Ophthalmic Solution and as such will be entitled to 180 days of marketing exclusivity.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.

Coal India reports production of 33.16 million tonnes in September 2013

Coal India, the world’s largest coal miner by output has reported provisional production of 33.16 million tonnes in September 2013, as against target of 33.58 million tonnes. The company’s total off-take for the month of September stood at 35.79 million tonnes as against a target of 34.84 million tonnes.

Coal India is the world’s largest coal mining company. It also produces non-coking coal and coking coal of various grades for diverse applications.